Results 111 to 120 of about 11,390 (145)

Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. [PDF]

Elife
Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW.   +6 more
europepmc   +1 more source

Aberrant cytoplasmic localization of MLH1 characterizes a cell population that seeds breast cancer recurrence. [PDF]

Nat Commun
Mazumder A, Dewitt J, Oropeza E, Punturi N, Lozano D, Raghunathan M, Piscitelli J, Sajjadi E, GueriniRocco E, Venetis K, Ivanova M, Mane E, Dercole M, Concardi A, Fusco N, Manhart C, Bainbridge M, Haricharan S.   +17 more
europepmc   +1 more source

Allosteric Mechanisms Triggering Substrate and Cofactor Binding in the SULT1A1 Dimer as Revealed by Molecular Dynamics Simulations. [PDF]

J Chem Inf Model
Toth D, Dudas B, Nicot AB, Miteva MA, Balog E.   +4 more
europepmc   +1 more source

Chinese expert consensus on endocrine therapy for breast cancer (2026 edition). [PDF]

Transl Breast Cancer Res
Yuan Y, Yin Y, Wang S, Liu Y, Yang J, Yan M, Mo X, Pan Y, Wang X, Wang H, Li J, Wang S, Wu J, Song E, Jiang Z, Chinese Consensus Group on Breast Cancer Endocrine Therapy.   +15 more
europepmc   +1 more source

Pharmacokinetics, safety and tolerability of ipatasertib in combination with palbociclib and fulvestrant in patients with advanced breast cancer in a phase Ib study. [PDF]

Front Pharmacol
Cheung KWK, Arzumanova K, Poon V, Harris A, Johnson R, Schimmoller F, Sane R.   +6 more
europepmc   +1 more source

Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib. [PDF]

In Vivo
Takada S, Umehara K, Watanabe K.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fulvestrant

Drugs, 2001
Fulvestrant is a 7alpha-alkylsulphinyl analogue of estradiol that competes with endogenous estrogen for binding to the estrogen receptor. Once bound to the receptor, fulvestrant attenuates receptor dimerisation, effecting a rapid degradation of the estrogen receptor protein and inhibition of transcription.
M, Curran, L, Wiseman
  +6 more sources